Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Live birth outcomes of vitrified embryos generated under growth hormone stimulation are improved for women categorized as poor-prognosis

  • Received : 2019.04.11
  • Accepted : 2019.07.19
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To determine the clinical pregnancy (CP) and live birth (LB) rates arising from frozen embryo transfers (FETs) that had been generated under the influence of in vitro fertilization (IVF) adjuvants given to women categorized as poor-prognosis. Methods: A registered, single-center, retrospective study. A total of 1,119 patients with first FETs cycle include 310 patients with poor prognosis (109 treated with growth hormone [GH], (+)GH group vs. 201 treated with dehydroepiandrosterone, (-)GH group) and 809 patients with good prognosis (as control, (-)Adj (Good) group). Results: The poor-prognosis women were significantly older, with a lower ovarian reserve than the (-)Adj (Good) group, and demonstrated lower chances of CP (p< 0.005) and LB (p< 0.005). After adjusting for confounders, the chances of both CP and LB in the (+)GH group were not significantly different from those in the (-)Adj (Good) group, indicating that the poor-prognosis patients given GH had similar outcomes to those with a good prognosis. Furthermore, the likelihood of LB was significantly higher for poor-prognosis women given GH than for those who did not receive GH (p< 0.028). This was further confirmed in age-matched analyses. Conclusion: The embryos cryopreserved from fresh IVF cycles in which adjuvant GH had been administered to women classified as poor-prognosis showed a significant 2.7-fold higher LB rate in subsequent FET cycles than a matched poor-prognosis group. The women with a poor prognosis who were treated with GH had LB outcomes equivalent to those with a good prognosis. We therefore postulate that GH improves some aspect of oocyte quality that confers improved competency for implantation.

Keywords

References

  1. Yovich JL, Stanger JD. Growth hormone supplementation improves implantation and pregnancy productivity rates for poorprognosis patients undertaking IVF. Reprod Biomed Online 2010;21:37-49. https://doi.org/10.1016/j.rbmo.2010.03.013
  2. Tesarik J, Hazout A, Mendoza C. Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian costimulation with growth hormone. Hum Reprod 2005;20:2536-41. https://doi.org/10.1093/humrep/dei066
  3. Bassiouny YA, Dakhly DM, Bayoumi YA, Hashish NM. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril 2016;105:697-702. https://doi.org/10.1016/j.fertnstert.2015.11.026
  4. Bayoumi YA, Dakhly DM, Bassiouny YA, Hashish NM. Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response. Int J Gynaecol Obstet 2015;131:305-8. https://doi.org/10.1016/j.ijgo.2015.05.034
  5. Lattes K, Brassesco M, Gomez M, Checa MA. Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in vitro fertilisation. Gynecol Endocrinol 2015;31:565-8.
  6. Eftekhar M, Aflatoonian A, Mohammadian F, Eftekhar T. Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstet 2013;287:1017-21. https://doi.org/10.1007/s00404-012-2655-1
  7. Haydardedeoglu B, Isik AZ, Kilicdag EB. The combination of dhea, transdermal testosterone and growth hormone as an adjuvant therapy in assisted reproductive technology in patients with dor below 40 years of age. Fertil Steril 2014;102:e221-2. https://doi.org/10.1016/j.fertnstert.2014.07.752
  8. Norman RJ, Alvino H, Hull LM, Mol BW, Hart RJ, Kelly TL, et al. Human growth hormone for poor responders: a randomized placebo- controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online 2019;38:908-15. https://doi.org/10.1016/j.rbmo.2019.02.003
  9. Ob'edkova K, Kogan I, Krikheli I, Dzhemlikhanova L, Muller V, Mekina I, et al. Growth hormone co-treatment in IVF/ICSI cycles in poor responders. Gynecol Endocrinol 2017;33(sup1):15-7. https://doi.org/10.1080/09513590.2017.1399693
  10. Norman RJ, Alvino H, Hart R, Rombauts L. A randomised double blind placebo controlled study of recombinant human growth hormone (r-HGH) on live birth rates in women who are poor responders. Hum Reprod 2016;31(Suppl 1):i37.
  11. Bevers MM, Izadyar F. Role of growth hormone and growth hormone receptor in oocyte maturation. Mol Cell Endocrinol 2002;197:173-8. https://doi.org/10.1016/S0303-7207(02)00270-8
  12. Keane KN, Yovich JL, Hamidi A, Hinchliffe PM, Dhaliwal SS. Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis. BMJ Open 2017;7:e018107. https://doi.org/10.1136/bmjopen-2017-018107
  13. Keane KN, Hinchliffe PM, Rowlands PK, Borude G, Srinivasan S, Dhaliwal SS, et al. DHEA supplementation confers no additional benefit to that of growth hormone on pregnancy and live birth rates in IVF patients categorized as poor prognosis. Front Endocrinol (Lausanne) 2018;9:14. https://doi.org/10.3389/fendo.2018.00014
  14. Xue-Mei W, Hong J, Wen-Xiang Z, Yang L. The effects of growth hormone on clinical outcomes after frozen-thawed embryo transfer. Int J Gynaecol Obstet 2016;133:347-50. https://doi.org/10.1016/j.ijgo.2015.10.020
  15. Cui N, Li AM, Luo ZY, Zhao ZM, Xu YM, Zhang J, et al. Effects of growth hormone on pregnancy rates of patients with thin endometrium. J Endocrinol Invest 2019;42:27-35. https://doi.org/10.1007/s40618-018-0877-1
  16. Chu K, Pang W, Sun N, Zhang Q, Li W. Outcomes of poor responders following growth hormone co-treatment with IVF/ICSI mild stimulation protocol: a retrospective cohort study. Arch Gynecol Obstet 2018;297:1317-21. https://doi.org/10.1007/s00404-018-4725-5
  17. Altmae S, Mendoza-Tesarik R, Mendoza C, Mendoza N, Cucinelli F, Tesarik J. Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donation program: a randomized controlled trial. J Endocr Soc 2017;2:96-105. https://doi.org/10.1210/js.2017-00359
  18. Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online 2005;11:300-8. https://doi.org/10.1016/S1472-6483(10)60837-1
  19. Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online 2012;24:281-92. https://doi.org/10.1016/j.rbmo.2011.11.014
  20. Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. Drug Des Devel Ther 2016;10:2561-73. https://doi.org/10.2147/DDDT.S104104
  21. Keane KN, Mustafa KB, Hinchliffe P, Conceicao J, Yovich JL. Higher ${\beta}$-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers. Reprod Biomed Online 2016;33:149-60. https://doi.org/10.1016/j.rbmo.2016.04.014
  22. Yovich JL, Conceicao JL, Stanger JD, Hinchliffe PM, Keane KN. Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biomed Online 2015;31:180-91. https://doi.org/10.1016/j.rbmo.2015.05.005
  23. Yovich JL, Conceicao J, Hinchliffe P, Keane K. Which blastocysts should be considered for genetic screening? Hum Reprod 2015;30:1743-4. https://doi.org/10.1093/humrep/dev105
  24. Gardner DK, Schoolcraft WB. In vitro culture of human blastocyst. In: Jansen R, Mortimer D, editors. Towards reproductive certainty: fertility and genetics beyond 1999. Carnforth: Parthenon; 1999. p. 378-88.
  25. Yovich JL, Stanger JD, Yovich JM, Tuvik AI. Quality of embryos from in-vitro fertilisation. Lancet 1984;1:457.
  26. Rosen MP, Johnstone E, Addauan-Andersen C, Cedars MI. A lower antral follicle count is associated with infertility. Fertil Steril 2011;95:1950-4. https://doi.org/10.1016/j.fertnstert.2011.01.151
  27. Almog B, Shehata F, Shalom-Paz E, Tan SL, Tulandi T. Age-related normogram for antral follicle count: McGill reference guide. Fertil Steril 2011;95:663-6. https://doi.org/10.1016/j.fertnstert.2010.08.047
  28. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979-87. https://doi.org/10.1016/j.fertnstert.2004.11.029
  29. Keane K, Cruzat VF, Wagle S, Chaudhary N, Newsholme P, Yovich J. Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome. Reprod Biol 2017;17:51-9. https://doi.org/10.1016/j.repbio.2016.12.002
  30. Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod 2014;29:1842-5. https://doi.org/10.1093/humrep/deu139
  31. Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of 'low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. F1000Res 2016;5:2911. https://doi.org/10.12688/f1000research.10382.1
  32. Izadyar F, Colenbrander B, Bevers MM. Stimulatory effect of growth hormone on in vitro maturation of bovine oocytes is exerted through the cyclic adenosine 3',5'-monophosphate signaling pathway. Biol Reprod 1997;57:1484-9. https://doi.org/10.1095/biolreprod57.6.1484
  33. Regan SL, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril 2018;110:1298-310. https://doi.org/10.1016/j.fertnstert.2018.08.018
  34. Ho YK, Lee TH, Lee CI, Cheng EH, Huang CC, Huang LS, et al. Effects of growth hormone plus gonadotropins on controlled ovarian stimulation in infertile women of advanced age, poor responders, and previous in vitro fertilization failure patients. Taiwan J Obstet Gynecol 2017;56:806-10. https://doi.org/10.1016/j.tjog.2017.10.018
  35. Hart RJ, Rombauts L, Norman RJ. Growth hormone in IVF cycles: any hope? Curr Opin Obstet Gynecol 2017;29:119-25. https://doi.org/10.1097/GCO.0000000000000360
  36. Yu X, Ruan J, He LP, Hu W, Xu Q, Tang J, et al. Efficacy of growth hormone supplementation with gonadotrophins in vitro fertilization for poor ovarian responders: an updated meta-analysis. Int J Clin Exp Med 2015;8:4954-67.
  37. Li XL, Wang L, Lv F, Huang XM, Wang LP, Pan Y, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6443. https://doi.org/10.1097/MD.0000000000006443
  38. Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2010;(1):CD000099.
  39. Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009;91:749-66. https://doi.org/10.1016/j.fertnstert.2007.12.077
  40. Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: a systematic review and meta-analysis. J Hum Reprod Sci 2016;9:70-81. https://doi.org/10.4103/0974-1208.183515
  41. Horcajadas JA, Riesewijk A, Polman J, van Os R, Pellicer A, Mosselman S, et al. Effect of controlled ovarian hyperstimulation in IVF on endometrial gene expression profiles. Mol Hum Reprod 2005;11:195-205. https://doi.org/10.1093/molehr/gah150

Cited by

  1. Clinical Outcomes of Frozen-Thawed Embryos Generated From Growth Hormone Stimulation in Expected Poor Responders vol.11, 2019, https://doi.org/10.3389/fendo.2020.608225
  2. A 10-Year Perspective on the Utility of Three Adjuvants Often Used in IVF: Growth Hormone, Melatonin and DHEA vol.2, pp.4, 2019, https://doi.org/10.3390/reprodmed2040016